Loading…
Loading…
The iShares Global Healthcare ETF provides broader exposure with 110 holdings across various sub-sectors compared to the 26 positions in the VanEck Pharmaceutical ETF The VanEck Pharmaceutical ETF features a lower expense ratio of 0.36% and a higher trailing dividend yield of 2.00% While the iShares Global Healthcare ETF has experienced lower historical drawdowns, the VanEck Pharmaceutical ETF has delivered higher total returns over the last five years
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
These ETF gainers of June may keep climbing in July as dovish Fed hopes, strong earnings and easing geopolitical risks support markets.
New York, July 07, 2026 (GLOBE NEWSWIRE) -- Namib Minerals (Nasdaq: NAMM) ("Namib Minerals" or the "Company") today announced a series of Board and executive leadership appointments to strengthen Board oversight, reinforce financial leadership and support the Company's next phase of growth, including the planned restart of the Redwing Mine and execution of its development financing strategy.
The VanEck Pharmaceutical ETF provides a lower expense ratio and a more substantial dividend yield than the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF delivered higher 1-year total returns but has lagged the VanEck fund over a 5-year horizon.
Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.